MBX Biosciences names chief medical officer
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Carmel-based MBX Biosciences Inc. announced Tuesday that it has appointed Dr. Salomon Azoulay as Chief Medical Officer.
The biopharmaceutical company, which focuses on developing peptide therapy treatments for endocrine and metabolic disorders, said Azoulay will oversee its global clinical development pipeline.
“It’s a privilege to join MBX Biosciences as the company enters this exciting stage of growth,” said Dr. Azoulay. “Endocrine and metabolic disorders are areas of significant unmet medical need. Based on compelling results achieved to date, I believe MBX’s precision peptides have the potential to change the landscape of how we treat these diseases. I look forward to working with the experienced MBX team and leveraging my clinical and drug development expertise to support the potential acceleration of our development pipeline.”
Azoulay has 35 years of experience in drug development and operations and has served as CMO at Roviant Sciences, Sumitovant Biopharma, and Pfizer.
According to the company, MBX has multiple drugs in its clinical development pipeline, including its lead product candidate MBX 2109, which is in Phase 2 development for the treatment of chronic hypoparathyroidism.